Key result
Two weeks of EGCG linked to reversal of TGFβ1-driven profibrotic state in pulmonary fibrosis.
Why the study?
The effect of epigallocatechin gallate (EGCG) on fibrotic markers in patients with pulmonary fibrosis was investigated to address profibrotic states.
Does epigallocatechin gallate (EGCG) improve levels of fibrotic markers in patients with pulmonary fibrosis?
Does epigallocatechin gallate (EGCG) improve levels of fibrotic markers in patients with pulmonary fibrosis?
A 2-week course of EGCG was evaluated for its effect on fibrotic markers in patients with pulmonary fibrosis undergoing lung biopsy.
EGCG and Pulmonary Fibrosis Nine patients who were scheduled to undergo lung biopsy for pulmonary fibrosis were given epigallocatechin gallate (EGCG) for 2 weeks. Levels of fibrotic markers in lung...
No takes yet. Share an insight, caveat, or question.
Chapman et al. (2020) studied this question. Epigallocatechin gallate (EGCG) given for 2 weeks reversed the TGFβ1-driven profibrotic state in patients with pulmonary fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: